Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Fundamental Analysis

NASDAQ:ALXO - US00166B1052 - Common Stock

1.135 USD
-0.03 (-2.99%)
Last: 8/25/2025, 10:48:08 AM
Fundamental Rating

1

Taking everything into account, ALXO scores 1 out of 10 in our fundamental rating. ALXO was compared to 547 industry peers in the Biotechnology industry. ALXO may be in some trouble as it scores bad on both profitability and health. ALXO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ALXO had negative earnings in the past year.
In the past year ALXO has reported a negative cash flow from operations.
In the past 5 years ALXO always reported negative net income.
In the past 5 years ALXO always reported negative operating cash flow.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ALXO has a Return On Assets of -122.30%. This is in the lower half of the industry: ALXO underperforms 79.52% of its industry peers.
ALXO has a Return On Equity of -180.97%. This is in the lower half of the industry: ALXO underperforms 64.17% of its industry peers.
Industry RankSector Rank
ROA -122.3%
ROE -180.97%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

ALXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALXO has more shares outstanding
ALXO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALXO has a worse debt to assets ratio.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ALXO has an Altman-Z score of -12.00. This is a bad value and indicates that ALXO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ALXO (-12.00) is worse than 75.87% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that ALXO is not too dependend on debt financing.
ALXO has a worse Debt to Equity ratio (0.13) than 65.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -12
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ALXO has a Current Ratio of 4.52. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
ALXO has a Current ratio of 4.52. This is comparable to the rest of the industry: ALXO outperforms 50.46% of its industry peers.
A Quick Ratio of 4.52 indicates that ALXO has no problem at all paying its short term obligations.
ALXO has a Quick ratio of 4.52. This is comparable to the rest of the industry: ALXO outperforms 51.37% of its industry peers.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

1

3. Growth

3.1 Past

ALXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.21%, which is quite impressive.
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ALXO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.83%
EPS Next 2Y27.8%
EPS Next 3Y18.84%
EPS Next 5Y23.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2028 2029 2030 2031 2032 100M 200M 300M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALXO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ALXO's earnings are expected to grow with 18.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.8%
EPS Next 3Y18.84%

0

5. Dividend

5.1 Amount

ALXO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (8/25/2025, 10:48:08 AM)

1.135

-0.03 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners61.32%
Inst Owner Change-17.17%
Ins Owners1.42%
Ins Owner Change7.19%
Market Cap60.78M
Analysts81.67
Price Target2.3 (102.64%)
Short Float %10.52%
Short Ratio5.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.12%
Min EPS beat(2)-22.55%
Max EPS beat(2)6.32%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-22.55%
Max EPS beat(4)27.1%
EPS beat(8)5
Avg EPS beat(8)0.34%
EPS beat(12)8
Avg EPS beat(12)2.09%
EPS beat(16)9
Avg EPS beat(16)-1.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.46%
PT rev (3m)-51.51%
EPS NQ rev (1m)10.14%
EPS NQ rev (3m)47.72%
EPS NY rev (1m)5.42%
EPS NY rev (3m)-1.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-2.14
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.3%
ROE -180.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z -12
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)208.08%
Cap/Depr(5y)2095.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.42%
EPS Next Y33.83%
EPS Next 2Y27.8%
EPS Next 3Y18.84%
EPS Next 5Y23.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.81%
EBIT Next 3Y17.54%
EBIT Next 5YN/A
FCF growth 1Y6.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.59%
OCF growth 3YN/A
OCF growth 5YN/A